|
JPS55102519A
(en)
|
1979-01-31 |
1980-08-05 |
Green Cross Corp:The |
Stabilization of interferon
|
|
US5670373A
(en)
|
1988-01-22 |
1997-09-23 |
Kishimoto; Tadamitsu |
Antibody to human interleukin-6 receptor
|
|
CA1332367C
(en)
|
1988-09-28 |
1994-10-11 |
Richard Mark Bartholomew |
Method for the reduction of heterogeneity of monoclonal antibodies
|
|
US5126250A
(en)
|
1988-09-28 |
1992-06-30 |
Eli Lilly And Company |
Method for the reduction of heterogeneity of monoclonal antibodies
|
|
IT1240314B
(it)
|
1989-09-28 |
1993-12-07 |
Immunobiology Research Institutes, Inc. |
Formulazioni acquose stabilizzate di piccoli peptidi.
|
|
EP0628639B1
(en)
|
1991-04-25 |
1999-06-23 |
Chugai Seiyaku Kabushiki Kaisha |
Reconstituted human antibody against human interleukin 6 receptor
|
|
AU7967294A
(en)
|
1993-10-06 |
1995-05-01 |
Board Of Regents, The University Of Texas System |
A monoclonal anti-human il-6 receptor antibody
|
|
US8017121B2
(en)
|
1994-06-30 |
2011-09-13 |
Chugai Seiyaku Kabushika Kaisha |
Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
|
|
US6309636B1
(en)
|
1995-09-14 |
2001-10-30 |
Cancer Research Institute Of Contra Costa |
Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
|
|
PT783893E
(pt)
|
1994-10-07 |
2012-05-24 |
Chugai Pharmaceutical Co Ltd |
Inibição do crescimento anormal das células sinoviais usando antagonistas de il-6 como componente ativo
|
|
CN1306963C
(zh)
|
1994-10-21 |
2007-03-28 |
岸本忠三 |
用于治疗il-6产生所致疾病的药物组合物
|
|
CA2226575C
(en)
|
1995-07-27 |
2011-10-18 |
Genentech, Inc. |
Stabile isotonic lyophilized protein formulation
|
|
DE19539574A1
(de)
|
1995-10-25 |
1997-04-30 |
Boehringer Mannheim Gmbh |
Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
|
|
TW518219B
(en)
|
1996-04-26 |
2003-01-21 |
Chugai Pharmaceutical Co Ltd |
Erythropoietin solution preparation
|
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
US20020187150A1
(en)
|
1997-08-15 |
2002-12-12 |
Chugai Seiyaku Kabushiki Kaisha |
Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
|
|
CZ20003099A3
(cs)
|
1998-02-25 |
2002-04-17 |
Lexigen Pharmaceuticals Corporation |
Zvýąení doby poloviční ľivotnosti cirkulujících fúzních proteinů odvozených od protilátek
|
|
DK1074268T3
(da)
|
1998-03-17 |
2008-04-28 |
Chugai Pharmaceutical Co Ltd |
IL-6-receptorantagonistantistofholdige forebyggende eller terapeutiske midler mod inflammatoriske tarmsygdomme
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
JP2000247903A
(ja)
|
1999-03-01 |
2000-09-12 |
Chugai Pharmaceut Co Ltd |
長期安定化製剤
|
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
DE10022092A1
(de)
|
2000-05-08 |
2001-11-15 |
Aventis Behring Gmbh |
Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
|
|
WO2002036165A1
(fr)
|
2000-10-27 |
2002-05-10 |
Chugai Seiyaku Kabushiki Kaisha |
Agent à base d'antagoniste d'il-6, faisant baisser le niveau des mmp-3 dans le sang
|
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
|
JP5290489B2
(ja)
|
2001-11-08 |
2013-09-18 |
アッヴィ・バイオセラピューティクス・インコーポレイテッド |
Igg抗体の安定な液体医薬製剤
|
|
BRPI0214168B8
(pt)
|
2001-11-14 |
2021-05-25 |
Centocor Inc |
anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
|
|
EP1573002A4
(en)
|
2002-02-11 |
2008-07-16 |
Genentech Inc |
ANTIBODY VARIANTS WITH FASTER ANTIGEN ASSOCIATION SPEEDS
|
|
AU2003211990A1
(en)
|
2002-02-14 |
2003-09-04 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody-containing solution pharmaceuticals
|
|
WO2005056606A2
(en)
|
2003-12-03 |
2005-06-23 |
Xencor, Inc |
Optimized antibodies that target the epidermal growth factor receptor
|
|
CA2492143A1
(en)
|
2002-07-12 |
2004-01-22 |
Medarex, Inc. |
Methods and compositions for preventing oxidative degradation of proteins
|
|
JP4463104B2
(ja)
|
2002-08-30 |
2010-05-12 |
財団法人化学及血清療法研究所 |
ヒト抗ヒトインターロイキン−6抗体及び該抗体フラグメント
|
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
DE60334141D1
(de)
|
2002-10-15 |
2010-10-21 |
Facet Biotech Corp |
VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
|
|
AU2003293543A1
(en)
|
2002-12-13 |
2004-07-09 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
|
KR101235507B1
(ko)
|
2003-02-28 |
2013-02-20 |
추가이 세이야쿠 가부시키가이샤 |
단백질을 함유하는 안정화 제제
|
|
US20050158303A1
(en)
|
2003-04-04 |
2005-07-21 |
Genentech, Inc. |
Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
|
|
CN1798575A
(zh)
|
2003-04-04 |
2006-07-05 |
健泰科生物技术公司 |
高浓度抗体和蛋白制剂
|
|
JP4685764B2
(ja)
|
2003-04-10 |
2011-05-18 |
アボット バイオセラピューティクス コーポレイション |
変異誘発による抗体のFcRn結合親和力又は血清半減期の改変
|
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
|
EP1644416A4
(en)
|
2003-06-30 |
2007-08-29 |
Centocor Inc |
ANTI-TARGET AND GENETICALLY MODIFIED IMMUNOGLOBULIN-DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
|
|
CN102408483B
(zh)
|
2003-07-15 |
2016-06-08 |
安姆根有限公司 |
作为选择性ngf途径抑制剂的人抗ngf中和抗体
|
|
WO2005035574A1
(ja)
|
2003-10-09 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
IgM高濃度安定化溶液
|
|
AU2003271174A1
(en)
|
2003-10-10 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
|
KR101193708B1
(ko)
|
2003-10-17 |
2012-10-22 |
추가이 세이야쿠 가부시키가이샤 |
중피종 치료제
|
|
AR048210A1
(es)
|
2003-12-19 |
2006-04-12 |
Chugai Pharmaceutical Co Ltd |
Un agente preventivo para la vasculitis.
|
|
WO2005063291A1
(ja)
|
2003-12-25 |
2005-07-14 |
Kirin Beer Kabushiki Kaisha |
抗体を含有する安定な水性医薬製剤
|
|
BRPI0506679A
(pt)
|
2004-02-11 |
2007-05-15 |
Warner Lambert Co |
métodos de tratar osteoartrite com antagonistas de il-6
|
|
AR048335A1
(es)
|
2004-03-24 |
2006-04-19 |
Chugai Pharmaceutical Co Ltd |
Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
|
|
US8398980B2
(en)
|
2004-03-24 |
2013-03-19 |
Chugai Seiyaku Kabushiki Kaisha |
Subtypes of humanized antibody against interleuken-6 receptor
|
|
KR20070035482A
(ko)
|
2004-03-24 |
2007-03-30 |
추가이 세이야쿠 가부시키가이샤 |
인터로킨-6 안타고니스트를 활성성분으로 함유하는내이장해 치료제
|
|
JP4939410B2
(ja)
|
2004-07-06 |
2012-05-23 |
バイオレン,インク. |
強化された特性を持つ変性ポリペプチドを発生させるためのルックスルー変異誘発
|
|
CN1842540B
(zh)
|
2004-07-09 |
2012-07-04 |
中外制药株式会社 |
抗-磷脂酰肌醇蛋白聚糖3抗体
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
JP5553963B2
(ja)
|
2004-10-22 |
2014-07-23 |
アムジエン・インコーポレーテツド |
組換え抗体をリフォールディングする方法
|
|
SG158150A1
(en)
|
2004-12-21 |
2010-01-29 |
Centocor Inc |
Anti-il-12 antibodies, epitopes, compositions, methods and uses
|
|
AU2005321017B2
(en)
|
2004-12-28 |
2011-02-24 |
Innate Pharma S.A. |
Monoclonal antibodies against NKG2A
|
|
WO2006112838A1
(en)
|
2005-04-18 |
2006-10-26 |
Xtl Biopharmaceuticals Ltd. |
Stabilized anti-hepatitis b (hbv) antibody formulations
|
|
PE20061324A1
(es)
|
2005-04-29 |
2007-01-15 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, metodos y usos
|
|
HUE029465T2
(en)
|
2005-08-10 |
2017-02-28 |
Macrogenics Inc |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
RU2446826C2
(ru)
|
2005-10-14 |
2012-04-10 |
Фукуока Юниверсити |
Агенты для подавления повреждения трансплантированных островков после трансплантации островков
|
|
AR058135A1
(es)
|
2005-10-21 |
2008-01-23 |
Chugai Pharmaceutical Co Ltd |
Agentes para el tratamiento de cardiopatias
|
|
TW200803894A
(en)
|
2005-11-25 |
2008-01-16 |
Univ Keio |
Prostate cancer therapeutic agents
|
|
US9084777B2
(en)
|
2005-12-28 |
2015-07-21 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilized antibody-containing formulations
|
|
CN101426527A
(zh)
|
2006-02-03 |
2009-05-06 |
米迪缪尼有限公司 |
蛋白质制剂
|
|
CA2638811A1
(en)
|
2006-02-03 |
2007-08-16 |
Medimmune, Llc |
Protein formulations
|
|
TW200806317A
(en)
|
2006-03-20 |
2008-02-01 |
Wyeth Corp |
Methods for reducing protein aggregation
|
|
US9670269B2
(en)
|
2006-03-31 |
2017-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of modifying antibodies for purification of bispecific antibodies
|
|
ES2892925T3
(es)
|
2006-03-31 |
2022-02-07 |
Chugai Pharmaceutical Co Ltd |
Métodos para controlar la farmacocinética en sangre de anticuerpos
|
|
CN101460622A
(zh)
|
2006-03-31 |
2009-06-17 |
中外制药株式会社 |
用于纯化双特异性抗体的抗体修饰方法
|
|
EP2025346B1
(en)
|
2006-04-07 |
2016-08-10 |
Osaka University |
Muscle regeneration promoter
|
|
CA2652733C
(en)
|
2006-05-25 |
2016-06-21 |
Glaxo Group Limited |
Modified humanised anti-interleukin-18 antibodies
|
|
ES2398076T3
(es)
|
2006-06-02 |
2013-03-13 |
Regeneron Pharmaceuticals, Inc. |
Anticuerpos de alta afinidad contra el receptor de IL-6 humano
|
|
US20080070230A1
(en)
|
2006-06-12 |
2008-03-20 |
Wyeth |
Methods for reducing or preventing liquid-liquid phase separation in high concentration protein solutions
|
|
EP2081553B1
(en)
|
2006-10-06 |
2020-08-12 |
Amgen Inc. |
Stable antibody formulations
|
|
JP2010512356A
(ja)
|
2006-12-11 |
2010-04-22 |
エフ.ホフマン−ラ ロシュ アーゲー |
非経口aベータ抗体製剤
|
|
JP5577098B2
(ja)
|
2006-12-21 |
2014-08-20 |
アムジエン・インコーポレーテツド |
ポリペプチドを含有する安定な緩衝化された製剤
|
|
CA2674608A1
(en)
|
2007-01-09 |
2008-07-17 |
Wyeth |
Anti-il-13 antibody formulations and uses thereof
|
|
GB0700523D0
(en)
|
2007-01-11 |
2007-02-21 |
Insense Ltd |
The Stabilisation Of Proteins
|
|
AU2008228823A1
(en)
|
2007-03-22 |
2008-09-25 |
Imclone Llc |
Stable antibody formulations
|
|
CA2682292A1
(en)
|
2007-03-30 |
2008-10-09 |
Medimmune, Llc |
Aqueous formulation comprising an anti-human interferon alpha antibody
|
|
GB0707938D0
(en)
|
2007-04-25 |
2007-05-30 |
Univ Strathclyde |
Precipitation stabilising compositions
|
|
US20110014676A1
(en)
|
2007-06-29 |
2011-01-20 |
Battelle Memorial Institute |
Protein stabilization
|
|
CN101796408B
(zh)
|
2007-06-29 |
2014-05-07 |
奎斯特诊断投资公司 |
用液相层析-质谱法分析体液内的氨基酸
|
|
EP2031064A1
(de)
|
2007-08-29 |
2009-03-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Verfahren zur Steigerung von Proteintitern
|
|
EP2206775B1
(en)
|
2007-09-26 |
2016-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-il-6 receptor antibody
|
|
CN101874042B9
(zh)
|
2007-09-26 |
2019-01-01 |
中外制药株式会社 |
利用cdr的氨基酸取代来改变抗体等电点的方法
|
|
AU2008304748C1
(en)
|
2007-09-26 |
2014-06-12 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant region
|
|
KR20150126724A
(ko)
|
2007-09-28 |
2015-11-12 |
추가이 세이야쿠 가부시키가이샤 |
혈장 중 반응속도가 개선된 항-글리피칸-3 항체
|
|
CA2708532C
(en)
|
2007-12-05 |
2018-06-05 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-il31ra antibody and use thereof
|
|
CN105816858B
(zh)
|
2007-12-28 |
2024-10-18 |
武田药品工业株式会社 |
重组vwf配方
|
|
KR102057826B1
(ko)
|
2008-04-11 |
2019-12-20 |
추가이 세이야쿠 가부시키가이샤 |
복수 분자의 항원에 반복 결합하는 항원 결합 분자
|
|
WO2009141239A1
(en)
|
2008-05-20 |
2009-11-26 |
F. Hoffmann-La Roche Ag |
A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
|
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
|
US20100292443A1
(en)
|
2009-02-26 |
2010-11-18 |
Sabbadini Roger A |
Humanized platelet activating factor antibody design using anti-lipid antibody templates
|
|
WO2010107110A1
(ja)
|
2009-03-19 |
2010-09-23 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
WO2010107108A1
(ja)
|
2009-03-19 |
2010-09-23 |
中外製薬株式会社 |
関節リウマチ治療剤
|
|
TWI682995B
(zh)
|
2009-03-19 |
2020-01-21 |
日商中外製藥股份有限公司 |
抗體恆定區域改變體
|
|
JP4885308B2
(ja)
|
2009-03-19 |
2012-02-29 |
中外製薬株式会社 |
改良された抗体分子を含有する製剤
|
|
AR080428A1
(es)
*
|
2010-01-20 |
2012-04-11 |
Chugai Pharmaceutical Co Ltd |
Formulaciones liquidas estabilizadas contentivas de anticuerpos
|
|
TWI603738B
(zh)
|
2010-11-08 |
2017-11-01 |
建南德克公司 |
皮下投予抗-il-6受體抗體
|
|
PH12016502073B1
(en)
|
2010-11-17 |
2024-04-05 |
Chugai Pharmaceutical Co Ltd |
Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
|
|
TWI812066B
(zh)
|
2010-11-30 |
2023-08-11 |
日商中外製藥股份有限公司 |
具有鈣依存性的抗原結合能力之抗體
|
|
CN112812184A
(zh)
|
2011-02-25 |
2021-05-18 |
中外制药株式会社 |
FcγRIIb特异性Fc抗体
|
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
|
TW201817744A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
|
EP3009518B1
(en)
|
2013-06-11 |
2020-08-12 |
National Center of Neurology and Psychiatry |
Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
|
|
JP6130983B2
(ja)
|
2015-02-27 |
2017-05-17 |
中外製薬株式会社 |
Il−6関連疾患治療用組成物
|
|
MA44780A
(fr)
|
2016-04-28 |
2019-03-06 |
Chugai Pharmaceutical Co Ltd |
Préparation contenant un anticorps
|
|
AR113142A1
(es)
|
2017-09-29 |
2020-01-29 |
Chugai Pharmaceutical Co Ltd |
Moléculas de unión al antígeno multiespecíficas que tienen actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii), y formulaciones farmacéuticas que contienen dicha molécula como ingrediente activo
|
|
AU2021278562A1
(en)
|
2020-05-29 |
2022-12-01 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody-containing formulation
|
|
JPWO2022191306A1
(https=)
|
2021-03-12 |
2022-09-15 |
|
|
|
WO2023095305A1
(en)
|
2021-11-26 |
2023-06-01 |
Chugai Seiyaku Kabushiki Kaisha |
Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab
|
|
CN118900699A
(zh)
|
2022-01-19 |
2024-11-05 |
中外制药株式会社 |
使用萨特利珠单抗治疗自身免疫性脑炎
|